Brought to you by www.DealSearchOnline.com
August 11, 2014 Issue:
Recent Health Care M&A Deals
Avalon Laboratories Holding Corp.
License for electrokinetic sensor technology
Global Rights to RSV drug
Ultragenyx Pharmaceutical Inc.
License to Triheptanoin
Roche Buys Santaris Pharma
Roche Holding Ltd. (OTCQX: RHHBY) has agreed to acquire Danish biotech firm Santaris Pharma A/S, for its proprietary locked nucleic acid (LNA) platform. Roche will make an upfront cash payment of $250 million to Santaris shareholders and additional contingent payments of up to $200 million based on the achievement of certain predetermined milestones. The deal is expected to close within this month.
July Health Care M&A Spending Tops $70 Billion
If you thought June was a busy month for healthcare transactions, you were probably blown away in July. Although June’s 112 deals were barely topped by July’s 117, spending soared. Thanks to the Pharmaceutical sector’s combined $68 billion in total spending, July 2014 weighed in at $70.7 billion in announced mergers and acquisitions. That’s not a record, but it’s close.
July Health Care M&A, by Segment, July vs. June 2014
Source: The Health Care M&A Information Source, August 2014
U.S. Physical Therapy Makes Second 2014 Acquisition
U.S. Physical Therapy, Inc. (NYSE: USPH), a national operator of outpatient physical therapy clinics, announced its second acquisition of the year, this time for an unidentified three-clinic practice. The price was $1.05 million for a business that sees approximately 10,500 patient visits per year. USPH described it as “a tuck-in acquisition” for one of its partnerships. It now operates 491 outpatient clinics in 42 states, and manages 17 PT facilities for third parties.
Cold Genesys Gets $13.57 Million Series A Funding
Cold Genesys, Inc., a clinical-stage oncolytic viral immunotherapy company in Newport Beach, California, announced it has secured Series A financing of $13.57 million from Ally Bridge Group, a global healthcare-focused investment group located in Hong Kong and the United States.Jul CGI will use the capital to advance its ongoing Phase 2/3 BOND trial, which is evaluating CG0070 in patients with high-risk carcinoma in situ non-muscle invasive bladder cancer. ……….Click here for a free trial to The Health Care M&A Information Source and download the current issue today.
The 2014 Hospital Acquisition Report – Free Webcast Offer!
There’s no quicker way to get current on the hospital M&A market or review historic hospital M&A data. Learn all about today’s hospital merger and acquisition market, not just what’s covered in major media. Order by August 31st and receive a FREE webcast: Key Growth Sectors in the Health-Care Services M&A Market. Go to http://www.levinassociates.com/landing/orderhos or call 800-248-1668 to order today.
The Health Care Services Acquisition Report, 20th Edition – Order Today!
Deals have been made. The 2014 Health Care Services Acquisition Report contains private deals in this market that are frequently too small to make it into the financial press. Order by August 31st and get a complimentary $150 of transactions in our online health care M&A database. Now that’s a deal! Go to http://www.levinassociates.com/landing/har20order or call 800-248-1668 to order today.
Sign up for a free trial subscription to Health Care M&A News!
Be the first to know. Don’t risk missing another day of this week’s biggest health care M&A deals! Sign up here.
Around the Web in Health Care M&A…Click here to see more
Webcast Calendar…Click here to see more
Upcoming Health Care M&A Investor Conferences… Click here to see more
Previous Issues of Health Care Deal News…Click here to see more